Is apalutamide (Ansenko) a targeted drug and an introduction to its treatment mechanism

Apalutamide (Apalutamide) is an oral androgen receptor inhibitor, which is a targeted drug (Targeted Therapy). It specifically acts on the androgen receptor (AR) to inhibit the androgen-dependent growth and proliferation of prostate cancer cells, thereby achieving tumor control. Unlike traditional chemotherapy drugs, apalutamide is highly targeted and has less impact on normal cells, so it belongs to the category of precision targeted therapy drugs.

Apalutamide blocks the binding of androgens to androgen receptors, inhibits the nuclear translocation of the receptors and the AR-mediated transcriptional activity, thereby blocking the signal transduction and growth stimulation of cancer cells. This mechanism can effectively delay tumor progression and is particularly suitable for patients with non-metastatic castration-resistant prostate cancer (nmCRPC), helping to control serum prostate-specific antigen (PSA) levels and improving progression-free survival.

In clinical studies, apalutamide has shown significant efficacy and can delay the occurrence of bone metastasis and distant metastasis. As a targeted drug, it is usually used in combination with castration therapy (such as GnRH analogues or testosterone inhibitors) to form a combined androgen deprivation therapy (ADT) regimen, thereby improving the accuracy and effectiveness of treatment.

Apalutamide is well tolerated, but adverse reactions such as rash, fatigue, thyroid dysfunction, and increased blood pressure may still occur. Blood pressure, liver function and thyroid function need to be monitored regularly during medication, and drug interactions need to be paid attention to. Standardized use and regular follow-up can not only ensure the efficacy of the drug, but also minimize the risk of side effects and provide patients with long-term and safe targeted treatment options.

Reference materials:https://www.drugs.com/